Health  Vol.7 No.12 , December 2015
Comparative Study on Management of Vitiligo with Psoralen plus Steroid (Oxabet Formula) Alone VS Psoralen Formula plus Narrow Band of Ultraviolet B 311 nm in Khartoum Teaching Hospital of Dermatology and Venereology (KTHDV)
ABSTRACT
A comparative study and management has been conducted in (KTHDV). For some patients who attend the out patients clinic concern on treatment of the vitiligo with a new formula (Oxabet) alone VS Oxabet (oxpsolaren plus betamethasone) formula plus NB. UVB311 is during a period from (Jan 2011-Jan 2013). The study sample includes different age groups of both sexes. The study revealed that the formula alone gives good results. The localized vitiligo has a good response to the formula than generalized one. The early lesions have good responses than the old ones. The continuations of applying the treatment and the follow up of the patients enhance the efficacy of the treatment.

Cite this paper
Mohammed, H. and Edriss, J. (2015) Comparative Study on Management of Vitiligo with Psoralen plus Steroid (Oxabet Formula) Alone VS Psoralen Formula plus Narrow Band of Ultraviolet B 311 nm in Khartoum Teaching Hospital of Dermatology and Venereology (KTHDV). Health, 7, 1763-1773. doi: 10.4236/health.2015.712192.
References
[1]   Lestery, M. and Alikhan, A. (2011) A Comprehensive Overview Part II Treatment Options and Approach to Treatment. Journal of American Academy of Dermatology: Vitiligo, 493-513.

[2]   (1998) Rook/Willkinson/Ebiling Text Book of Dermatology. 6th Edition, Black Well Science Ltd., 1802-1805.

[3]   Andrews Diseases of the Skin Clinical Dermatology, 10th Edition, El Sevier Inc., 7531-8734.

[4]   Fitzpatricks (2007) Dermatology in General Medicine. 6th Edition, Wilkinson/Ebiling, 823-847.

[5]   Khanaa, N. (2009) All Illustrate Synopsis of Dermatology and Sexually Transmitted Diseases. Elsevier, 129-135.

[6]   Behi, P.N. Practice of Dermatology. 10th Edition, Salih Kummer, India, 204-304-310.

[7]   Bowers, K.E. (2002) Manual of Dermatologic Therapeutics. 6th Edition, Luppinco William & Wikins, 118-120.

[8]   Shelleg, W.B. and Shelley, E.D. (2002) Advance Dermatology Therapy. Luppinco William & Wikins, 1179-1186.

[9]   Refael Fulabella and Marial, Borna Update an Skin Repigmentation Therapies in Vitiligo. Publication 17 Novem-ber.
refalabella@uniweb.net.co

[10]   Magid, I. (2010) Vitiligo Management: An Update, British. Journal of Medical Practioners, 3.

[11]   Eldir, D.E. (2005) Lever’s Histopathology of the Skin. 9th Edition, Lippincott Williams & Winkins, Philadelphia, 710-711.

[12]   Harn, S.K. and Lee, H.J. (1996) Segmental Vitiligo: Clinical Findings in 208 Patients. Journal of the American Academy of Dermatology, 35, 671-674.
http://dx.doi.org/10.1016/S0190-9622(96)90718-5

[13]   Schallreuter, K.U., Wood, J.M., Pielkow, M.R., Buttner, G., Swanson, N., Korner, C. and Ehrke, C. (1996) Increased Monoamine Oxidase A Activity in the Epidermis of Patients with Vitiligo. Archives of Dermatological Research, 288, 14-18.
http://dx.doi.org/10.1007/BF02505037

[14]   Alkhateeb, A., Fain, P.R., Thody, A., Bennett, D.C. and Spirtz, R.A. (2003) Epidemiology of Vitiligo and Associated Autoimmune Diseases in Caucasian Probands and Their Families. Pigment Cell Research, 16, 208-214.
http://dx.doi.org/10.1034/j.1600-0749.2003.00032.x

[15]   Nath, S.K., Majumder, P.P. and Van Nordlund, J.J. (1994) Genetic Epidemiology of Vitiligo: Multilocus Recessivity Cross-Validated. American Journal of Human Genetics, 55, 981-990.

[16]   Bystryn, J.C., Riget, D., Friedman, R.J. and Kopf, A. (1987) Prognostic Significance of Hypopigmentation in Malignant Melanoma. Archives of Dermatology, 123, 1053-1055.
http://dx.doi.org/10.1001/archderm.1987.01660320095019

[17]   Naralond, J.J., Kirkwood, J.M., Forget, S.M., Milton, G., Albert, D.M. and Lerner, A.B. (1983) Viltiligo in Patients with Metastatic Melanoma: A Good Prognostic Sign. Journal of the American Academy of Dermatology, 9, 689-696.
http://dx.doi.org/10.1016/S0190-9622(83)70182-9

[18]   Alajlan, A., Alfadley, A. and Pedersen, K.T. (2002) Transfer of Vitiligo after Allogeneic Bone Marrow Transplantation. Journal of the American Academy of Dermatology, 46, 606-610.
http://dx.doi.org/10.1067/mjd.2002.117215

[19]   Aubin, F., Calm, J.Y., Ferrand, C., Angonmn, R., Humbert, P. and Tberghien, P. (2000) Extensive Vitiligo after Ganciclovir Treatment of GvHD in a Patient Who Had Received Donor T Cells Expressing Herpes Simplex Virus Thymidine Kinase. Lancet, 355, 626-627.
http://dx.doi.org/10.1016/S0140-6736(99)04215-4

[20]   Bystryn, J.C. (1989) Serum Antibodies in Vitiligo Patients. Clinics in Dermatology, 7, 136-145.
http://dx.doi.org/10.1016/0738-081X(89)90063-1

[21]   Cui, J., Harning, B., Henn, M. and Bystryn, J.C. (1992) Identification of Pigment Cell Antigens Defined by Vitiligo Antibodies. Journal of Investigative Dermatology, 98, 162-165.
http://dx.doi.org/10.1111/1523-1747.ep12555773

[22]   Cui, J., Arita, Y. and Bystryn, I.C. (1995) Characterization of Vitiligo Antigens. Pigment Cell Research, 8, 53-59.
http://dx.doi.org/10.1111/j.1600-0749.1995.tb00774.x

[23]   Norris, D.A., Capin, L., Muglia, I.I., Osborn, R.L., Zerbe, G.O., Bystrjn, C. and Tonneseni, M.G. (1988) Enhanced Susceptibility of Melanocytes to Different Immunologic Effector Mechanisms in Vitro: Potential Mechanisms for Postinflammatory Hypopigmentation and Vitiligo. Pigment Cell Research, 1, 113-123.
http://dx.doi.org/10.1111/j.1600-0749.1988.tb00801.x

[24]   Song, Y.H., Connar, E., Li, Y., Zorovrich, B., Baidaccl, P. and Maclaren, N. (1994) The Role of Tyrosinase in Autoimmune Vitiligo. Lancet, 344, L1049-L1052.
http://dx.doi.org/10.1016/s0140-6736(94)91709-4

[25]   Hedstrand, H., Ekwall, O., Olsson, M.J., Landgren, E., Kemp, E.H., Weetman, A.P., et al. (2001) The Transcription Factors SOX9 and SOX10 Are Vitiligo Autoantigens in Autoimmune Polyendocrine Syndrome Type I. The Journal of Biological Chemistry, 276, 35390-35395.
http://dx.doi.org/10.1074/jbc.M102391200

[26]   Baharav, E., Merimski, O., Shoenfeld, Y., Zigelman, B., Gilbrud, B., Yechskl, G., et al. (1996) Tyrosinase as an Autoantigen in Patients with Vitiligo. Clinical & Experimental Immunology, 105, 84-88.
http://dx.doi.org/10.1046/j.1365-2249.1996.d01-727.x

[27]   Cui, J., Arita, Y. and Bystryn, J.C. (1993) Cytolytic Antibodies to Melanocytes in Vitiligo. Journal of Investigative Dermatology, 100, 812-815.
http://dx.doi.org/10.1111/1523-1747.ep12476636

[28]   Harning, R., Cui, J. and Bystryn, I.C. (1991) Relation between the Incidence and Level of Pigment Cell Antibodies and Disease Activity in Vitiligo. Journal of Investigative Dermatology, 97, 1078-1080.
http://dx.doi.org/10.1111/1523-1747.ep12492607

[29]   Norris, D.A., Kissinger, R.M., Naughton, G.M. and Bystryn, J.C. (1988) Evidence for Immunologic Mechanisms in Human Vitiligo: Patients’ Sera Induce Damage to Human Melanocytes in Vitro by Complement-Mediated Damage and Antibody-Dependent Cellular Cytotoxicity. Journal of Investigative Dermatology, 90, 783-789.
http://dx.doi.org/10.1111/1523-1747.ep12461505

[30]   Schallreuter, K.U., Wood, J.M., Ziegler, I., Lemke, K.R., Pittelkow, M.R., Lindsey, N.J. and Gütlich, M. (1994) Defective Tetrahydrobiopterin and Catecholamine Biosynthesis in the Depigmentation Disorder Vitiligo. Biochimica et Biophysica Acta, 1226, 181-192.
http://dx.doi.org/10.1016/0925-4439(94)90027-2

[31]   Thappa, D.M. (2008) Textbook of Dermatology, Leprology & Venereology. 3rd Edition, Elsevier, Amsterdam, 196-200.

[32]   Arndt, K.A., Hsu, J.T.S., Alam, M., Bhatia, A. and Chilukuri, S. (2002) Manual of Dermatologic Therapeutics. 8th Edition, Lippincott Williams & Wilkins, Philadelphia, 119-123.

 
 
Top